Ranked No. 7 on the list, the eight-year-old company had a 1,939 percent growth in five years and reached a revenue of nearly $245 million in 2013, according to Crain’s Chicago Business. Based in Schaumburg, Sagent specializes in developing and distributing generic injectable pharmaceuticals.
Sagent was rated No. 1 on Crain’s Chicago list last year. The ranking is based on a company’s five-year revenue growth.
In 2013, three new cancer drugs boosted revenue 30 percent and helped the company book its first net profit, Crain’s reports, and Sagent also made bank filling the national injectable-drug shortage.
Instead of pouring capital into buildings, the company has benefited from creating partnerships with manufacturers around the world and launching products just as branded versions lose patent protection.
Last year, Sagent capitalized on the health care market in China by buying out a partner, Chengdu Kanghong Pharmaceuticals Group Co. Ltd., in a Chinese joint venture and constructed a factory in the southern city of Chengdu.
With more than 40 years of injectable pharmaceutical experience, Yordon was the original founding member of Gensia Laboratories, LyphoMed, Faulding Pharmaceuticals and American Pharmaceutical Partners, now called Fresenius.
Yordon received his bachelor’s degree in political science from Northern Illinois University in 1970. He has shown dedication to his alma mater as a member of the NIU Foundation board, a director of the Executive Leadership Forum board and an alumni adviser to the athletics department. He has also taught as a visiting professor for the NIU College of Business and College of Liberal Arts and Sciences.